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Abstract: The effects of remote ischemic preconditioning (RIPC) in cardiac surgery have
been inconsistent. We investigated whether anesthesia or beta-blockers interfere with RIPC
cardioprotection. Fifty patients undergoing cardiac surgery were randomized to receive limb RIPC
(four cycles of 5-min of upper arm cuff inflation/deflation) in the awake state (no-anesthesia;
n = 17), or under sevoflurane (n = 17) or propofol (n = 16) anesthesia. In a separate crossover study,
11 healthy volunteers received either carvedilol or no medication prior to RIPC. Plasma dialysates
were obtained and perfused through an isolated male Sprague–Dawley rat heart subjected to 30-min
ischemia/60-min reperfusion, following which myocardial infarct (MI) size was determined. In the
cardiac surgery study, pre-RIPC MI sizes were similar among the groups (39.7 ± 4.5% no-anesthesia,
38.9 ± 5.3% sevoflurane, and 38.6 ± 3.6% propofol). However, post-RIPC MI size was reduced
in the no-anesthesia group (27.5 ± 8.0%; p < 0.001), but not in the anesthesia groups (35.7 ± 6.9%
sevoflurane and 35.8 ± 5.8% propofol). In the healthy volunteer study, there was a reduction in
MI size with RIPC in the no-carvedilol group (41.7 ± 4.3% to 30.6 ± 8.5%; p < 0.0001), but not in
the carvedilol group (41.0 ± 4.0% to 39.6 ± 5.6%; p = 0.452). We found that the cardioprotective
effects of limb RIPC were abolished under propofol or sevoflurane anesthesia and in the presence of
carvedilol therapy.
Keywords: ischemic preconditioning; remote ischemic conditioning; cardiac surgery;
cardioprotection; ischemia-reperfusion injury; carvedilol; propofol; sevoflurane
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1. Introduction
New treatment strategies are required to improve clinical outcomes in patients with ischemic heart
disease, the leading cause of death and disability worldwide. Remote ischemic preconditioning (RIPC),
in which brief cycles of non-lethal ischemia and reperfusion are applied to an organ or tissue away
from the heart, has been shown to protect the myocardium against lethal acute ischemia/reperfusion
(IR) injury [1]. This strategy, which can be non-invasively applied by simply inflating and deflating
a pneumatic cuff placed on the upper arm to induce cycles of brief IR (termed limb RIPC), has been
shown to reduce procedure-related myocardial injury in patients undergoing elective percutaneous
coronary intervention [2] as well as myocardial infarct (MI) size in ST-segment elevation myocardial
infarction patients [3–5].
In the setting of coronary artery bypass graft (CABG) surgery, several studies have shown a
reduction in peri-operative myocardial injury with limb RIPC as evidenced by attenuated release of
cardiac biomarkers such as cardiac troponins [6,7]. However, three large clinical studies in cardiac
surgery have failed to show any benefits of limb RIPC on post-surgical clinical outcomes [8–10].
The reasons for this are unclear but have been attributed to several factors including the use of
propofol [11,12]. However, there has been no direct demonstration that propofol blocks the effects of
RIPC [13]. It has also been suggested that beta-blockers (BBs) may interfere with RIPC by attenuating
organ protection or altering RIPC-related signaling pathways [14].
The mechanisms underlying the cardioprotective effects of limb RIPC are not clear, although a
neuro-humoral pathway linking the limb to the heart has been implicated [15]. In previous studies
focused on the parasympathetic system, blocking these signaling pathways attenuated the effects
of RIPC [15,16]. However, few studies have been conducted on the sympathetic nervous system.
With respect to the humoral pathway, the cardioprotective effects of RIPC can be transferred between
species [17–20]. Therefore, the effects of RIPC can be evaluated by transferring the protective factors
from human plasma dialysate to the rat heart perfusion system subjected to acute IR injury [18].
We hypothesized that propofol attenuates the cardioprotective effects of RIPC in cardiac surgery
patients. To evaluate our hypothesis, we used a Langendorff-perfused rat heart model to investigate
whether propofol or volatile anesthetic, sevoflurane affects the cardioprotective effects of limb RIPC
in cardiac surgery patients. In addition, we investigated the effects of BB, carvedilol treatment on
RIPC-induced myocardial protection in healthy volunteers.
2. Results
Cardiac surgery patients were enrolled between 22 February 2017 and 16 January 2018. Among
the 162 patients screened, 111 were excluded and 51 were allocated to the no-anesthetic, sevoflurane,
and propofol groups (Figure 1a). One patient in the propofol group was excluded as he did not
meet the inclusion criteria, thus 50 patients were included in the final analyses. In one patient in the
sevoflurane group, there was an intraoperative event due to suspected injury of the left coronary artery.
Therefore, data on troponin levels for this patient were excluded from the analyses.
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Figure 1. Study flow diagram of: (a) cardiac surgery patients; and (b) healthy volunteers. Figure 1. Study flow diagram of: (a) cardiac surgery patients; and (b) healthy volunteers.
Eleven healthy volunteers were recruited between 17 May 2017 and 25 October 2017 and
completed the protocol (Figure 1b). No complications related to RIPC or the use of carvedilol were
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detected. There was one experimental failure with the Langendorff model each in the no-anesthesia
and carvedilol group, due to the sustained poor ventricular contractile function and the poor contractile
function combined with sustained ventricular fibrillation, respectively. Therefore, these data were
excluded from the analyses. Study participants’ characteristics are shown in Tables 1 and 2.
Table 1. Characteristics of cardiac surgery patients.
Characteristics
Cardiac Surgical Patients
p ValueNo-Anesthesia
(n = 17)
Sevoflurane
(n = 17) Propofol (n = 16)
Age (yr) 66 ± 14 59 ± 15 63 ± 15 0.453
Male sex 6 (35%) 13 (77%) 7 (41%) 0.040
Height (cm) 158.1 ± 11.9 168.7 ± 10.4 160.4 ± 8.3 0.011
Weight (kg) 62.5 ± 10.5 66.4 ± 10.3 62.2 ± 8.1 0.395
BMI (kg/m2) 25.0 ± 3.5 23.2 ± 2.4 24.2 ± 3.0 0.242
BSA (m2) 1.6 ± 0.2 1.8 ± 0.2 1.7 ± 0.1 0.082
Smoking status
(never/current/ex-smoker) 16 (94%)/1 (6%)/0
11 (64%)/3
(18%)/3 (18%)
12 (75%) /2 (12%)
/2 (12%) 0.314
Baseline LV EF (%) 62 ± 6 60 ± 7 59 ± 8 0.480
Baseline troponin I
(ng/mL) 0.007 ± 0.014 0.018 ± 0.038 0.026 ± 0.049 0.332
Baseline hematocrit (%) 40 ± 3 41 ± 6 39 ± 4 0.357
Baseline eGFR
(mL/min/1.73m2) 78.1 ± 19.3 86.9 ± 20.6 88.5 ± 27.7 0.371
Comorbidities No-Anesthesia Sevoflurane Propofol
Hypertension 8 (47%) 2 (12%) 6 (37%) 0.075
Diabetes mellitus 2 (12%) 1 (6%) 3 (18%) 0.524
Ischemic heart disease 3 (19%) 1 (6%) 1 (6%) 0.456
Previous PCI 2 (12%) 2 (12%) 0 0.360
Previous stroke 1 (6%) 0 0 0.371
Preoperative medication No-Anesthesia Sevoflurane Propofol
Aspirin 7 (41%) 4 (24%) 2 (13%) 0.165
Clopidogrel 1 (6%) 1 (6%) 0 0.613
ACE inhibitor 0 0 1 (6%) 0.338
ARB 2 (12%) 2 (12%) 3 (18%) 0.802
CCB 9 (53%) 4 (24%) 3 (18%) 0.071
Diuretics 7 (41%) 4 (24%) 6 (37%) 0.520
Nitroglycerin 0 0 1 (6%) 0.338
Digoxin 0 1 (6%) 1 (6%) 0.584
OHA 0 1 (6%) 3 (18%) 0.129
Insulin 0 1 (6%) 0 0.371
Statin 8 (47%) 4 (24%) 5 (31%) 0.337
Type of surgery No-Anesthesia Sevoflurane Propofol 0.381
Valve 8 (47%) 10 (59%) 13 (82%)
Valve + Aorta 7 (41%) 5 (29%) 1 (6%)
Valve + CABG 1 (6%) 0 1 (6%)
Aorta 1 (6%) 1 (6%) 1 (6%)
Other* 0 1 (6%) 0
Data are presented as mean ± SD or number (%). * Other surgery indicates repair of ventricular septal defect. BMI,
body mass index; BSA, body surface area; LV EF, left ventricular ejection fraction; eGFR, estimated glomerular
filtration rate; PCI, percutaneous coronary intervention; ACE, angiotensin converting enzyme; ARB, angiotensin
receptor blocker; CCB, calcium channel blocker; OHA, oral hypoglycemic agent; CABG, coronary artery bypass graft.
Table 2. Characteristics of healthy volunteers.
Characteristics Healthy Volunteers(n = 11)
Age (yr) 27 ± 6
Height (cm) 174.1 ± 4.8
Weight (kg) 71.3 ± 8.2
BMI (kg/m2) 23.5 ± 2.2
BSA (m2) 1.9 ± 0.1
Data are presented as mean ± SD. BMI, body mass index; BSA, body surface area.
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According to our preliminary data, MI size of rat hearts (control group, n = 3) that were perfused
for 30 min and then underwent IR injury, consisting of 30-min global ischemia followed by 60-min
reperfusion, without treatment of human dialysate, was 41.1 ± 6.8%. For the control group, no other
interfering substances but only neutral buffer solution was used to perfuse the isolated rat heart.
In addition, we confirmed that the freezing process before cutting and staining the heart slices did not
induce negative staining in sham hearts (n = 2) by performing negative control experiments, in which
the hearts were excised, frozen at −20 ◦C for 30 min, cut into slices and then stained (Figure 2).
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In the cardiac surgery study, pre-RIPC MI sizes were similar among the three cardiac surgery
groups (39.7 ± 4.5% no-anesthesia, 38.9 ± 5.3% sevoflurane, and 38.6 ± 3.6% propofol; p = 0.785).
However, MI size was significantly reduced after RIPC in the no-anesthesia group (post-RIPC MI size,
27.5 ± 8.0%; mean difference −12.1%; 95% CI −17.4%, −6.9%; p < 0.001), but not in the two anesthetic
groups (35.7 ± 6.9% sevoflurane and 35.8 ± 5.8% propofol) (Figure 3). Post-RIPC MI size in the
sevoflurane group was inferior to that of the no-anesthesia group (mean difference, −8.1% (one-sided
97% CI −13.5%, ∞), p > 0.999; non-inferiority test), but did not differ from that of the propof l gr up
(p = 0.957).
Int. J. Mol. Sci. 2019, 20, 269 6 of 18
Int. J. Mol. Sci. 2018, 19, x 6 of 18 
 
Figure 3. Comparison of pre- and post-RIPC infarct size of the Langendorff isolated rat heart model 
using dialysate from cardiac surgery patients under different anesthetic implication. Data are 
presented as mean ± SD. * p < 0.05 compared to the pre-RIPC infarct size within a group. LV, left 
ventricle; RIPC, remote ischemic preconditioning. 
In the healthy volunteer study, there was a significant reduction in MI size with RIPC in the no-
carvedilol group (41.7 ± 4.3% pre-RIPC vs. 30.6 ± 8.5% post-RIPC; mean diﬀerence −10.6%; 95% CI 
−14.7%, −6.5%; p < 0.0001) (Figure 4). However, in the carvedilol group, there was no significant 
difference in MI size (41.0 ± 4.0% pre-RIPC vs. 39.6 ± 5.6% post-RIPC; mean diﬀerence −1.6%; 95% CI 
−5.9%, 2.8%; p = 0.452). There was no carry-over effect of the first period treatment (p = 0.216). 
Figure 3. Comparison of pre- and post-RIPC infarct size of the La lated rat heart model
using dialys te from cardiac surgery patients under different anesthetic implicat on. D a are present d
as mean ± SD. * p < 0.05 compared to the pre-RIPC infarct size within a group. LV, left ventricle; RIPC,
remote ischemic preconditioning.
In the ealthy volunte r study, t a significant reductio in MI size with RIPC in the
no-c r il l r ( . .3 r - I s. .6 8.5% post-RIPC; mean difference−10.6%; 95% CI
−14.7%, −6.5%; p < 0.0001) (Figure 4). o ever, in the carvedilol group, there was no significant
difference in MI size (41.0 ± 4.0% pre-RIPC vs. 39.6 ± 5.6% post-RIPC; mean difference −1.6%; 95% CI
−5.9%, 2.8%; p = 0.452). There was no carry-over effect of the first period treatment (p = 0.216).
Int. J. Mol. Sci. 2019, 20, 269 7 of 18Int. J. Mol. Sci. 2018, 19, x 7 of 18 
 
Figure 4. Comparison of pre- and post-RIPC infarct size of the Langendorff isolated rat heart model 
using dialysate from healthy volunteers with or without taking beta-blocker. Data are presented as 
mean ± SD. * p < 0.05 compared to the pre-RIPC infarct size within a group. LV, left ventricle; RIPC, 
remote ischemic preconditioning. 
There were no differences in postoperative variables among the groups of patients (Table 3). 
Table 3. Postoperative variables in cardiac surgery patients. 
Variables 
No-Anesthesia 
(n = 17) 
Sevoflurane 
(n = 17) 
Propofol  
(n = 16) p Value 
Peak troponin I in 72 h (ng/mL) 13.07 ± 8.02 11.92 ± 7.33 * 17.44 ± 20.01 0.456 
Chest tube drain in 24 h (mL) 697 ± 433 859 ± 538 739 ± 612 0.656 
New onset atrial fibrillation 5 (31%) 7 (41%) 7 (47%) 0.671 
Intensive care unit stay (h) 42 ± 28 35 ± 27 42 ± 36 0.743 
Postoperative hospital stay (days) 12 ± 6 10 ± 4 11 ± 8 0.618 
Figure 4. Comparison of pre- and post-RIPC infarct size of t e a gendorff isolated rat heart model
using dialysate from healthy volunteers with or without taking beta-blocker. Data are presented as
mean ± SD. * p < 0.05 compared to the pre-RIPC infarct size within a group. LV, left ventricle; RIPC,
remote ischemic preconditioning.
There were no differences in postoperative variables among the groups of patients (Table 3).
Table 3. Postoperative variables in cardiac surgery patients.
Variables No-Anesthesia(n = 17)
Sevoflurane
(n = 17)
Propofol
(n = 16) p Value
Peak troponin I in 72 h (ng/mL) 13.07 ± 8.02 11.92 ± 7.33 * 17.44 ± 20.0 0.456
Chest tube drain in 24 h (mL) 697 ± 43 859 ± 538 739 ± 612 0.656
New onset atrial fibrillation 5 (31%) 7 (41%) 7 (47%) 0.671
Intensive care unit stay (h) 42 ± 28 35 ± 27 42 ± 36 0.743
Postoperative hospital stay (days) 12 ± 6 10 ± 4 11 ± 8 0.618
Data are presented as mean ± SD or number (%). * One patient in the sevoflurane group who had intraoperative
event related to suspicious left coronary artery injury was excluded from the comparison of postoperative
troponin level.
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3. Discussion
In this study, when patients were not under anesthesia, the dialysate from the patients post-RIPC
reduced MI size of rat hearts following acute IR injury. However, RIPC-induced cardioprotection was
attenuated when the patients were under either sevoflurane or propofol anesthesia. There were no
differences between the two anesthetics. In healthy volunteers, the use of carvedilol attenuated the
RIPC-induced cardioprotection.
Since it was first described in 1993 [21], many trials have applied RIPC in various settings,
showing conflicting results. RIPC applied to human subjects has elicited myocardial protection and
improved clinical outcomes in patients undergoing primary coronary intervention [2,22,23]. However,
in patients undergoing cardiac surgery involving CABG and/or cardiac valve surgery, RIPC has
not provided beneficial implication on clinical outcomes beyond the reduction in myocardial injury
markers [24,25]. In three large multi-center trials involving more than 1000 patients undergoing
cardiac surgery, RIPC failed to have benefits on composite clinical outcomes [8–10]. The reason for the
discrepancy in clinical results has not yet been well investigated and remains undetermined [19,25].
There have been many attempts to identify possible confounding factors that may interfere with
RIPC. In the aforementioned trials, which all showed a neutral effect of RIPC on outcomes after cardiac
surgery, most patients received propofol during RIPC [8–10], and the use of propofol was proposed as
the main factor responsible for the results. Propofol (2,6-diisopropylphenol) is a lipid-soluble anesthetic
agent that contains a phenolic structure similar to the phenol-based free radical scavenger α-tocopherol,
which is a natural antioxidant [26]. In an in vivo rat study, propofol attenuated small intestinal IR
injury by suppressing oxidative stress [27]. Because treatment with free radical scavengers abolished
the volatile-induced preconditioning effects [28,29], it is plausible that the free radical scavenging
ability of propofol might attenuate the effects of RIPC [30].
There have been several clinical trials supporting this hypothesis. In a previous small trial in
patients undergoing CABG, RIPC reduced postoperative cardiac troponin I (cTnI) under isoflurane
anesthesia, but did not under propofol anesthesia [31]. In another trial, sub-group analyses showed
that the use of propofol abrogated the effects of RIPC after CABG [7]. Furthermore, when the use of
propofol was precluded, RIPC reduced acute kidney injury in high-risk surgical patients [32].
In this study, we found that RIPC did not protect myocardium against IR injury in isolated
rat heart under either sevoflurane or propofol anesthesia. According to our results, propofol did
not act differently from sevoflurane in attenuating the effects of RIPC. There are several possible
explanations. First, the concentration of propofol administered during the study period (approximately
40 min) may not have reached the concentration required to have cardioprotective effects [33]. Second,
both sevoflurane and propofol attenuated oxidative stress by reducing reactive oxygen species [34],
suggesting that both might interfere with RIPC. Third, general anesthesia itself, regardless of anesthetic
agents, may suppress the neurogenic pathways of RIPC. Traditionally, inhibiting the afferent and
efferent nerve pathways are two of the four components of general anesthesia [35]. Thus, it is possible
that the neurogenic pathways of RIPC could be suppressed during general anesthesia. In a recent
Cochrane review, subgroup analyses provided no definite conclusion on whether propofol interfered
with or inhibited the effects of RIPC [36].
The results of our study are not consistent with a recent work by Behmenburg and colleagues [37],
who investigated the impact of different anesthetic regimens on RIPC in an animal model. In that
study, pentobarbital and sevoflurane applied to rats preserved the effects of RIPC, whereas
propofol completely abolished the protection when comparing MI sizes. However, while animal
experiments and pre-clinical studies have promising results, the clinical application of RIPC is
more complex. Human patients are in a very different condition from healthy experimental
animals. Most clinical studies, including ours, are conducted in diseased patients undergoing
surgical procedures. Our patients are typically elderly, have various comorbidities and have been
taking comedications. RIPC dialysate from diabetic patients with peripheral neuropathy mitigated
cardioprotective effects [18], and comedications such as angiotensin receptor blocker could interfere
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with ischemic conditioning [38]. Accordingly, under sevoflurane anesthesia, RIPC elicited protective
effects in children with congenital heart defects [39], but not in adults with comorbidities [40].
Nevertheless, the plasma dialysate from the patients received RIPC without anesthetics showed
significant cardioprotection in rat hearts in our study.
In this study, a single administration of carvedilol abrogated the effects of ischemic conditioning
in healthy volunteers. Among several explanations for this observation, BB may have blocked the
neurogenic pathways of RIPC, as muscarinic receptor blockers or vagotomy blocked the effects
of RIPC [15,16]. Similar to propofol, carvedilol acts as a free radical scavenger [41,42], thereby
inhibiting the effects of ischemic conditioning in animal studies. Thus, there is also a possibility
that carvedilol might have blocked effects of RIPC by its anti-oxidative properties regardless of
blockade of beta-adrenoceptors in this study. Chronic pre-treatment with propranolol and nipradilol
abrogated the effects of ischemic preconditioning in rat hearts [43]. A brief treatment of short-acting
BB, esmolol, also attenuated the effects of ischemic preconditioning in rabbit hearts [14]. In addition,
beta-adrenergic blockade with atenolol abrogated the beneficial effects of preconditioning in isolated
mouse hearts [44]. However, retrospective analyses of clinical studies showed no impact of BB on
RIPC-induced cardioprotection in patients undergoing CABG surgery [45]. Therefore, further studies
are required to elucidate the effects of carvedilol on RIPC.
In addition, opioid receptors are implicated in myocardial conditioning and cardioprotective
responses [46]. Continuous administration of remifentanil provided cardioprotection in in vitro
human myocardium against hypoxia reoxygenation stress [47]. On the other hand, sustained
administration of remifentanil inhibited preconditioning-induced infarct limitation following one
cycle of preconditioning (5-min ischemia and 5-min reperfusion), but did not affect MI size reduction
elicited by two cycles of preconditioning in rabbit hearts [48]. In this study, we investigated the
effects of sevoflurane and propofol on RIPC-induced cardioprotection in a pragmatic manner that is
commonly used in clinical anesthetic practice for cardiac surgery patients. Nevertheless, we cannot
completely exclude any influence of remifentanil administered during RIPC in this study, and further
studies are required to determine the effects of administered remifentanil during RIPC in cardiac
surgery patients.
This study has several limitations. First, this study does not provide insight on mechanism by
which propofol, sevoflurane, or carvedilol treatment diminishes the production, transfer or translation
of RIPC signals. However, these issues are beyond of the scope of this study and should be investigated
in further studies. Second, the sample size calculation was based on the MI size of the rat hearts treated
with plasma dialysate. Accordingly, the limited number of enrolled patients elicited heterogeneity in
the baseline characteristics. Future studies may limit the study population to a homogenous group
to reduce the heterogeneity but this may also reduce external validity. Third, the included patients
mostly had valvular heart diseases, whereas most previous studies on RIPC involved patients with
ischemic heart disease [9,10,22,23]. However, patients undergoing valve surgery are also susceptible
to IR injury and are candidates for organ protection, although their disease entity is diverse. Fourth,
calculation of the MI size of rat hearts did not take into account the weight of the heart slices, and
only areas were used. Lastly, clinical parameters apart from the primary outcome were not adequately
powered. Moreover, the anesthetic technique was standardized with propofol-based anesthesia in all
groups after RIPC. Therefore, we should be careful in interpreting the results on other outcomes, such
as troponin levels.
4. Materials and Methods
4.1. Ethical Approval
The studies in patients and healthy volunteers were approved by the Institutional Review Board
of Seoul National University Hospital (1605-079-761, 20 July 2016 and 1702-031-829, 3 March 2017)
and registered at clinicaltrials.gov (NCT02932722 and NCT03169426) before enrollment. The study
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was performed according to Good Clinical Practice guidelines and the principles of the Declaration of
Helsinki. All participants provided written informed consent and were allowed to withdraw their
consent at any time. All animal experimental protocols were approved by the Institutional Animal
Care and Use Committee (IACUC) of Seoul National University (SNU-160812-2-2, 20 April 2017 and
SNU-170417-22, 4 May 2017) and were in accordance with the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (NIH, Bethesda, MD, USA).
4.2. Study Population
For the cardiac surgery study, patients aged 20–80 years old and undergoing cardiac surgery using
cardiopulmonary bypass at Seoul National University Hospital were eligible for inclusion. We did
not include over-octogenarian patients, as any possible changes in neuronal or humoral responses
to RIPC in these patients were not clearly identified. Patients were excluded if they met any of the
following criteria: undergoing descending thoracic aorta surgery; engaged in strenuous exercise,
alcohol or caffeine intake within 24 h prior to surgery; preoperative left ventricular (LV) ejection
fraction <30%; uncontrolled hypertension or diabetes mellitus; severe renal or hepatic dysfunction;
receiving hemodialysis; presence of arterio-venous fistula on arms; peripheral vascular or nerve
disease; coagulopathy; preoperative use of BBs; preoperative use of mechanical circulatory support
devices; emergent or redo operation; refusal to enroll; or were pregnant.
For the healthy volunteers study, healthy male volunteer aged 20–45 years old were recruited by
local advertising. Subjects were excluded based on the following criteria: use of any prescribed or
over-the-counter drugs; allergic history to any food or medication; body mass index < 18 or > 30 kg/m2;
baseline systolic blood pressure (BP) > 150 mmHg or < 100 mmHg, or diastolic BP > 100 mmHg or
< 50 mmHg; strenuous exercise, consumption of tobacco or alcohol or caffeine-containing materials
within 24 h prior to study; use of herbal medications within 14 days; presence of problems such as
vascular abnormalities on the upper extremities that precluded RIPC; or did not consent to participate.
4.3. Randomization and Masking
Enrolled cardiac surgery patients were randomized to one of the following three treatment
groups: no-anesthesia, sevoflurane, or propofol on the day of surgery (Figure 1a). Block randomization
(blocks of six or nine) was conducted using a computer-generated randomization program by an
independent researcher to allocate patients in a 1:1:1 ratio. Group assignment was concealed in
opaque envelopes and blinded to surgeons and investigators involved in animal experiments and
data analyses. The animal studies and data analyses were undertaken by investigators blinded to the
treatment allocation.
Using a randomized, two-treatment, two-period crossover study design, healthy male volunteers
received either a single oral dose of carvedilol 12.5 mg (carvedilol group) or no medication
(no-carvedilol group). Randomization codes were generated by a computer, sealed in opaque envelops
and assigned to the subjects after enrollment. Each study protocol was separated by a washout period
of six days (Figure 1b).
4.4. Cardiac Surgery Study Design
Without premedication, patients were monitored with 5-lead electrocardiogram, non-invasive
BP, pulse oximetry, bispectral index, and cerebral oximetry. Arterial cannulation for continuous BP
monitoring was established at the radial artery. In the no-anesthesia group, RIPC was performed in the
awake state before anesthesia on the day of surgery (Figure 5). General anesthesia was provided to the
patients in the no-anesthesia group after RIPC study protocol during the surgery. In the sevoflurane
and propofol groups, RIPC was commenced after the induction of anesthesia (Figure 5). Anesthesia
was induced with midazolam 1 mg/kg in the sevoflurane group, while effect-site concentration of
propofol (Fresofol 2 MCT 2%, Fresenius Kabi, Graz, Austria) 4 µg/kg/min with target-controlled
infusion in the propofol group. During RIPC, maintenance doses of anesthetics were 2 vol% of
Int. J. Mol. Sci. 2019, 20, 269 11 of 18
sevoflurane (Sojourn, Piramal Critical Care Inc., Bethlehem, PA, USA) and 4 µg/kg/min of propofol
in the sevoflurane and propofol groups, respectively. Continuous infusion of remifentanil (Ultiva,
GlaxoSmithKline, Middlesex, UK) was used in both groups. After completion of RIPC, anesthesia was
maintained with propofol and remifentanil in all groups. The RIPC protocol consisted of four cycles of
5-min ischemia and 5-min reperfusion induced by inflating the pneumatic cuff on the upper arm to
200 mmHg, and deflating the cuff, respectively.
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4.5. Healthy Volunteer Study Design
Study prot c ls were performed in a quiet r ine position. Subjects w re asked to
remain il per os for more tha i r to each investigation, and were allowed to rest for 5 min
in supine pos tion prior to the investigation. During the s udy, three-lead electroc rdiogram,
non-invasive BP, and pulse oximetry w re monitored. RIPC was co menced 90 min after taking
carvedilol in the carvedilol group, or after 5 min of rest in the no-carvedilol group (Figure 6).
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4.6. Preparation of Human Plasma Dialysate
Blood samples (30 mL) were obtained from the participants before (pre-RIPC) and after completion
of RIPC (p st-RIPC). In the cardiac surgery p tients randomized to receive sevoflurane or propofol,
pre-RIPC samples were collected befo anesth tic administra ion. The blood was collected in sodium
heparin tubes an i m diately centrifuged at 3000 rpm for 20 min at room temperature (Figure 7).
The plasma fraction was carefully separated ithout disturbing the buffy coat, and was dialyzed
across a 12–14 kDa dialysis tubing membrane (Spectra/Por, Spectrum Laboratories, Inc., Rancho
Dominguez, CA, USA) against a 20-fold volume of modified Krebs–Henseleit buffer (KHB) for 24 h at
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4 ◦C. If the plasma could not be used immediately, it was stored in a −80 ◦C freezer. Modified KHB for
dialysis consisted of 118 mM NaCl, 4.7 mM KCl, 1.1 mM MgSO4·7H2O, 1.2 mM KH2PO4, and 1.8 mM
CaCl2·2H2O. Prior to perfusion of the rat heart, the dialysate was supplemented with 25 mM NaHCO3
and 11 mM D-glucose, gassed with a 95% O2 and 5% CO2 mixture, and equilibrated to 37 ◦C. Finally,
the pH was adjusted to 7.4.
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4.7. Langendorff-Perfused Rat Heart Model
Male Sprague–Dawley rats, age eighing 250–350 g, w re housed under
specific pathogen-free conditions on a 12-h/ li t/dark cycle with free access t food and water.
The environmental temperature and humidity ere ai tai e at 24–25 ◦C and 40–60%. All animals
were cared for in strict compliance to the uidelines for Care and Use of Laboratory Animals issued
by the IACUC of Seoul National University. Rats were anesthetized with intraperitoneal injections of
60 mg/kg of pentobarbital sodium or inhalation of 6–8 vol% sevoflurane. Among the 100 anesthetized
rats used in the cardiac surgery study, 10 were given pentobarbital sodium and the remaining rats were
given sevoflurane due to the shortage of pentobarbital in our animal laboratory. Forty-four rats used
in the healthy volunteer study were anesthetized with sevoflurane. The duration of the inhalation of
sevoflurane until the opening of the thorax was less than 2 min. Therefore, although we cannot exclude
the possibility of any effects of inhaled sevoflurane in rats completely, any additive cardioprotective
effects induced by this brief period of inhalation would have affected MI size equally among the
treatment groups. Heparin (100 IU/kg) was administered via a lateral tail vein. After confirming
the loss of pedal reflex, the hearts were rapidly excised via a clamshell thoracotomy, mounted on
a Langendorff-apparatus within 1 min via ascending aorta cannulation, and perfused with KHB
solution in a retrograde, non-recirculating manner. KHB consisted of 118 NaCl, 25 mM NaHCO3,
11 mM D-glucose, 4.7 mM KCl, 1.1 mM MgSO4·7H O, 1.2 mM KH2PO4, and 1.8 mM CaCl2·2H2O,
was gassed with a 95% O2 and 5% CO2 mixture, an adjusted to a pH of 7.4 t 37 ◦C. Following
10-min stabilization, the heart was pe fused w th pre- or post-RIPC dialysate for 15 min and then
wash d out for 5 min prior to 30-min no-flow global ischemia and subsequent 60-min reperfusion
(Figure 8) [49–51]. Eac heart w s tr ated only with one certain plasma dialysate from one human
subject. The temperature of the heart was maintained at 37 ◦C. Hearts were excluded if they met one
of the following exclusion criteria: time to perfusion >3 min; unstable contractile function; significant
arrhythmic duration >3 min; or heart rate <100 or >400 beats per minute.
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At the completion of i n, the hearts w removed from the appar tus and placed at
−20 ◦C for 30 min [ 0–52]. The semi-frozen hearts were cut into 5–6 slices transversely, each 1–2 mm
thick. T n the slices were incubated in 1% 2,3,5- riphenyltetrazolium chloride in 0.1 M sodium
phosphate buffer adjusted to pH 7.4, at 37 ◦C for 15 min to distinguish viabl tissue (brick red color)
and infarcted tissue (pale white color). The slices were fixed in 10% formalin solution for 24 h for
contrast enhancement. Then, both sides of the slices were digitally scanned for planimetric analyses
by a blinded observer using ImageJ software (ver 1.51, NIH, Bethesda, MD, USA). Because the hearts
were subjected to global ischemia, the total cross-sectional LV areas were defined as the total areas at
risk, and MI size was expressed as a percentage of the total area of the LV [20,51–53]. The reported MI
size is the mean of all MI measurements from both sides of all individual slices.
4.8. Study Endpoints and Sample Size Calculation
The primary endpoint of the cardiac study was MI size of the rat heart perfused with human
dialysate. Previously, the MI size in a Langendorff IR injury model using human dialysate was
27.4 ± 3.8% [54]. Based on this, we hypothesized that the MI size in the sevoflurane group would be
comparable to that of the no-anesthesia group, and that the MI of the propofol group would differ
from that of the sevoflurane group. We calculated the sample size at a significance level of 2.5% for
each hypothesis with a power of 80%. For testing non-inferiority of sevoflurane compared to the
no-anesthesia regarding post-RIPC MI size, 13 patients per group were required for non-inferiority
margin of 5%, which was chosen by clinical relevance, including a 10% dropout rate. For comparison
of the sevoflurane and propofol groups, we calculated that 17 patients were required per group to
detect a clinically relevant percent change in MI of 20% between g oups, assuming a 10% dropout
rate. Based on these calculations, we decided to enroll 17 patients per group (a total of 51 patients in
the study).
Secondary endpoints included the difference in MI changes between the carvedilol and
no-carvedilol groups. Other study endpoints in cardiac surgery patients included postoperative
variables, such as peak level of cTnI during postoperative 72 h, amount of chest tube drain during
the first postoperative 24 h, newly occurred atrial fibrillation, duration of intensive care unit stay,
and postoperative hospital stay. Evaluation of cTnI was performed using the Abbott ARCHITECT
analyzer (Abbott Laboratories, Abbott Park, IL, USA), which has a limit of detection of 0.001 ng/mL
and an overall 99th percentile of 0.026 ng/mL. A cTnI level higher than 0.028 ng/mL was considered
abnormal. New instances of postoperative atrial fibrillation were identified based on the presence of
sustained atrial fibrillation on patients’ electrocardiographic monitors that required medical treatment
or direct-current cardioversion.
4.9. Statistical Analyses
Data are expressed as mean ± SD, median (IQR (range)), number (proportion), or mean
difference with 95% confidence intervals (CIs). The normality of the data was tested using the
Kolmogorov–Smirnov test and Shapiro–Wilk test. Continuous variables were compared using the
independent t-test, one-way analysis of variance, or Mann–Whitney U test. Categorical variables were
compared using Pearson’s chi square test or Fisher’s exact test. For the analysis of primary endpoint,
non-inferiority of sevoflurane to no-anesthetic with regard to post-RIPC MI size was evaluated using
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one-sided t-test at a significance level of 0.025, and post-RIPC MI size between sevoflurane and propofol
group was compared using two-sided t-test at a significance level of 0.025. In the non-inferiority test of
sevoflurane comparing to no-anesthetic, a p-value to reject the null hypothesis of mean post-RIPC MI
size in the no-anesthetic group is at least 5% less than those in the sevoflurane group was reported.
For comparison of pre- and post-RIPC MI size within a group, paired t-test with correction for multiple
testing was used. For the secondary endpoints, comparison of MI size changes between the carvedilol
and no-carvedilol group in the 2 × 2 crossover study was analyzed using a linear mixed model
with treatment, period, sequence, and pre-RIPC MI size as fixed effects and subject as a random
effect. Healthy volunteers were randomized to the carvedilol or no-carvedilol group. Volunteers
were then crossed over to the alternate group after a washout period of six days. Residuals versus
fitted values plots were used to check that the error terms (residuals) had a mean of zero and constant
variance. The plots did not have any pattern opposed to the equal variance assumption. The normality
assumption for the model residuals was checked with histograms and normal quantile–quantile plots
of residuals, which seemed to be normally distributed. Analyses were performed using SPSS software
(ver. 21.0, IBM, Armonk, NY, USA) and SAS software (ver. 9.2, SAS institute, Cary, NC, USA) for
Microsoft Windows. A p value < 0.05 was considered statistically significant.
5. Conclusions
RIPC-induced cardioprotection was attenuated under sevoflurane or propofol anesthesia in
patients undergoing cardiac surgery. There were no differences between sevoflurane and propofol
anesthesia. The use of carvedilol also abolished the effects of RIPC in healthy volunteers. These data
suggest that sevoflurane, propofol and carvediolol treatment inhibit the effects of RIPC and should be
considered in future research. Our research may also explain in part why recent clinical studies of limb
RIPC in cardiac surgery have been neutral.
Author Contributions: Conceptualization, S.J.K., D.J.H. and Y.J.; Data curation, K.N. and T.K.K.; Formal analysis,
Y.J.C., D.J.H. and Y.J.; Funding acquisition, D.J.H. and Y.J.; Investigation, Y.J.C. and S.W.C.; Methodology, K.N. and
T.K.K.; Resources, T.K.K., S.W.C. and S.J.K.; Software, Y.J.C., K.N. and S.W.C.; Supervision, S.J.K., D.J.H. and Y.J.;
Validation, D.J.H. and Y.J.; Visualization, Y.J.C. and K.N.; Writing—Original Draft, Y.J.C.; and Writing—Review
and Editing, S.J.K., D.J.H. and Y.J.
Funding: This study was supported by a research grant from the National Research Foundation of Korea
(Grant Number 2017R1D1A1B030319999/2018014927) and Seoul National University Hospital (Grant Numbers
0420160740 and 0420160560). Derek Hausenloy was supported by the British Heart Foundation (FS/10/039/28270),
the National Institute for Health Research University College London Hospitals Biomedical Research Centre,
Duke-National University Singapore Medical School, Singapore Ministry of Health’s National Medical Research
Council under its Clinician Scientist-Senior Investigator scheme (NMRC/CSA-SI/0011/2017) and Collaborative
Centre Grant scheme (NMRC/CGAug16C006), and the Singapore Ministry of Education Academic Research
Fund Tier 2 (MOE2016-T2-2-021). This article is based upon work from COST Action EU-CARDIOPROTECTION
CA16225 supported by COST (European Cooperation in Science and Technology). The funding sources and
sponsors had no role in the current study design; in the collection, analysis, and interpretation of data; in the
writing of this paper; and in the decision to submit the paper for publication.
Acknowledgments: We thank the Medical Research Collaborating Center for their advice concerning the statistical
analyses. We appreciate Sau Rezendiz and Jooah Kwak for their support in our animal experiments.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to
publish the results.
Int. J. Mol. Sci. 2019, 20, 269 15 of 18
Abbreviations
RIPC remote ischemic preconditioning
BB beta-blocker
MI myocardial infarct
IR ischemia/reperfusion
CABG coronary artery bypass graft
cTnI cardiac troponin I
IACUC Institutional Animal Care and Use Committee
LV left ventricular
BP blood pressure
CI confidence interval
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